For the ALT pathway, higher activity was noticed in the normal tumor-adjacent samples of prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), and cancer cells of cholangiocarcinoma (CHOL), and STAD. This evidence concerns the gene GPT and cutaneous melanoma.